The biggest consumer acquisition announced in 2026 was not a viral DTC brand. On June 15, Prestige Consumer Healthcare closed a $1.045 billion deal for Breathe Right, a nasal strip launched in the 1990s, at roughly 11 times EBITDA. The price went to proven, asset-light, high-margin demand, not to a growth story.
- Prestige paid $1.045 billion in cash, about $900 million net of an expected $150 million tax benefit.
- The acquired brands generate roughly $200 million in revenue and $95 million in EBITDA, close to a 47% EBITDA margin.
- That works out to about 11x EBITDA and 5.2x sales: a disciplined multiple, not a story multiple.
- Danone reportedly paid around 22x EBITDA for Huel. The gap between 11x and 22x is the gap between a profitable brand and a category bet.
The single biggest consumer brand acquisition announced in 2026 was not Poppi, not a viral greens powder, and not a buzzy skincare line. It was Breathe Right, the nasal strip your dad wore to stop snoring in 1998. On June 15, 2026, Prestige Consumer Healthcare closed its $1.045 billion purchase of Breathe Right and a handful of other over-the-counter brands from Foundation Consumer Healthcare. Founders building toward a billion-dollar exit should read that sentence twice.
I read acquisitions from both sides of the table. At WIN Brands Group I built the kind of challenger brands that end up on a corporate target list, and I later sourced and closed a several-hundred-million dollar DTC acquisition for an S&P 500 buyer, advising the corporate side. The Breathe Right deal is a clean teardown of what a strategic actually underwrites when it writes a ten-figure check in this market, because almost none of it is about growth.
The headline is the $1.045 billion. The number that should change how you build is the multiple under it. The acquired brands do roughly $200 million in revenue and about $95 million in EBITDA, so Prestige paid close to 11 times EBITDA and roughly 5.2 times sales. Net of an expected $150 million tax benefit, the effective price is nearer $900 million, or about 9.5 times EBITDA. That is a disciplined, defensible multiple, and it is less than half what Danone reportedly paid for Huel in the same broad window.
So the most expensive consumer deal of the year was also one of the most conservative on a multiple basis. That is the whole lesson. Strategics in 2026 will pay a very large absolute number for proven, profitable, asset-light demand, and they will discount a growth story hard. If you want the wider pattern, the spring 2026 wave I broke down in the consumer M&A window post says the same thing from a different angle. Breathe Right is the cleanest single proof of it.
The whole deal,
on one page.
Here is the transaction with nothing dressed up. One serial buyer, one anchor brand, a clean asset purchase, and a price built on cash flow rather than narrative.
| Item | Detail |
|---|---|
Buyer | Prestige Consumer Healthcare (NYSE: PBH) |
Seller | Foundation Consumer Healthcare |
Assets | Breathe Right nasal strips plus certain other OTC brands |
Price | $1.045B cash ~$900M net of an expected $150M tax benefit |
Acquired financials | ~$200M revenue · ~$95M EBITDA ~47% EBITDA margin |
Timeline | Announced March 20, 2026 · closed June 15, 2026 |
Financing | Cash on hand plus a new Term Loan B |
Breathe Right becomes Prestige's largest brand and pushes the company into a category it did not previously play in. For a buyer whose entire model is owning durable, low-maintenance over-the-counter brands, that is the definition of a clean bolt-on. Nothing here required Prestige to believe a story. It required them to believe an income statement, which is a very different kind of underwriting than the one most DTC pitch decks invite.
What eleven times
actually means.
Run the same price through three lenses and the discipline jumps out. Eleven times EBITDA on a 47 percent margin brand is not a number you reach for when you are paying for potential. It is the number you reach for when the cash flow is already there and you are buying the right to keep it.
| Lens | Figure | What it tells you |
|---|---|---|
Headline price | ~$1.045B | The number in the press release. |
Net of tax benefit | ~$900M | The effective cash cost after a ~$150M tax benefit. |
EBITDA multiple | ~11.0× ~9.5× net of tax | Disciplined. Strategics pay this for proven, durable cash flow. |
Sales multiple | ~5.2× | High on sales because the margin is unusually high. |
EBITDA margin | ~47% | The real tell. This is an asset-light, license-grade margin. |
The 47 percent EBITDA margin is the part that earns the multiple. A brand that converts nearly half of revenue into operating profit is not spending its life buying demand on Meta and Google. It owns shelf, owns recognition, and throws off cash with very little ongoing investment. That is exactly the profile a public acquirer can finance with a term loan and pay down quickly, which is precisely what Prestige told the market it would do: use the brand's free cash flow to deleverage.
"The most expensive consumer deal of 2026 was also one of the most disciplined on a multiple. That is not a contradiction. It is the entire point."
Now hold that 11 times next to the story multiples founders quote to each other. Danone reportedly paid in the neighborhood of 22 times EBITDA for Huel. PepsiCo paid $1.95 billion for Poppi in 2025. Those are category-conviction prices, paid when a buyer believes a brand will define an expanding space. They are real, but they are the exception. The Breathe Right multiple is the one a finance committee signs without a fight, and it is a far better template for what your brand can actually command. The difference usually shows up first in a contribution margin teardown, where a brand with strong gross margins but thin profit after shipping, returns, and media gets revalued the moment a corporate finance team models it forward.
Why a nasal strip beat
every DTC darling
on the board.
Put a 30-year-old nasal strip next to a three-year-old DTC rocket ship and ask which one a strategic would rather own in 2026. The answer in this market is almost always the nasal strip, and the reasons are not sentimental.
Breathe Right is demand that has already been proven across three decades and every major retail shelf. It does not depend on a paid-media engine that evaporates the day a corporate owner trims the ad budget. Its margin survives diligence because the margin is real, not a function of this quarter's blended CAC. And it slots onto distribution Prestige already controls, so the integration risk is low and the fit is obvious. A buyer can underwrite every one of those things from a spreadsheet.
Compare the typical DTC darling doing $200 million in revenue. If it is getting there on heavy paid acquisition at an 8 to 12 percent EBITDA margin, a corporate finance team will model it without the founder's ad spend, watch the growth flatten, and mark the price down accordingly. The brand that looked like a rocket in the pitch becomes a question mark in diligence. This is the same screen enterprise teams run when they think through the challenger brand threat model: are we buying a community, a channel position, or a durable product, because the price and the integration risk are different for each.
What strategics
underwrite in 2026.
Cash flow, not curves.
The through-line in this deal, and in nearly every disciplined consumer transaction this year, is that buyers are paying for demand that has already been proven and profitability that survives a model. The era when a strategic would pay up for a steep top-line curve and figure out the economics later is over. Capital costs more, boards are less forgiving, and the deals that clear are the ones a CFO can defend on cash flow alone.
For a brand, that reorders what matters. Margin is not a finishing touch you add before a sale, it is the asset. A defensible category position you can describe in one sentence beats a longer growth story. And asset-light operations, the kind that do not require the buyer to keep feeding the machine, command a premium because they convert cleanly into the buyer's portfolio. The specific number a strategic will defend internally usually comes back to the EBITDA margin that makes a brand sellable in the first place.
There is a financing tell here too. Prestige funded a billion-dollar purchase partly with a Term Loan B and told investors the brand's free cash flow would pay it down. You can only do that with a brand that genuinely throws off cash. A buyer cannot deleverage on the back of a brand that needs continued investment just to hold its position. So the asset-light, high-margin profile is not just attractive, it is what makes the whole capital structure of the deal work. That is the quiet reason proven brands keep winning the biggest checks.
If you're building to sell,
build the brand a buyer
can underwrite.
The practical takeaway for a founder is not to go invent a nasal strip. It is to build toward the profile that earned the price. A brand a strategic can underwrite in 2026 has a real EBITDA margin, a category position it leads or co-leads, demand that holds when the ad budget gets cut, and operations clean enough that a corporate owner does not inherit a mess. If your exit thesis depends on a billion-dollar bidding war, you are building for the rare exception. If it depends on being the most profitable, most defensible brand in a category a strategic wants, you are building for the buyer who is actually signing checks.
Concretely, that means treating margin as a feature rather than something you will fix later, resisting the raise that only pencils at a fantasy valuation, and protecting the first-party customer relationship that survives a change of ownership. Most founders anchor on the wrong comp. The Breathe Right deal and the Miss Mouth's deal both point at the same realistic ceiling for a well-run brand, which is why the $325M exit breakdown is a more useful planning tool than any billion-dollar headline. Reverse-engineering a $300 to $500 million outcome is a plan. Reverse-engineering a billion is a lottery ticket.
The timing question is where founders most often hurt themselves. Sell too early and the brand is not differentiated enough to command a premium. Wait too long, after raising at a valuation that prices out every realistic buyer, and a winnable exit turns into a down round. The sweet spot tends to arrive when you have a clear category position, 18 to 24 months of profitability at a defensible margin, and at least two strategic buyers who would each be worse off if the other owned you. One motivated buyer is a negotiation. Two is an auction.
If you're the buyer,
this is the disciplined
acquirer's playbook.
Prestige is not a household name, and that is rather the point. It is a serial owner of durable over-the-counter brands, Summer's Eve, Compound W, Clear Eyes, Chloraseptic and a long tail of others, run on a consistent model: buy the leader in a small, sleepy category, fold it onto existing distribution, run it for cash, and use that cash to pay down the debt that financed the purchase. Breathe Right is that playbook at its largest scale yet. There is no reinvention, just a bigger bolt-on that fits the machine.
For any corporate or sponsor buyer, the lesson is the one I keep coming back to with enterprise teams. Know your shelf cold, keep a live target list in your priority categories, pay for free cash flow rather than narrative, and move quickly when a clean asset comes available from a motivated seller. The buyers who do this well treat acquisition as an operating discipline, not a periodic event. The ones who do it poorly wait too long, then overpay defensively, a pattern I walk through in the DTC acquisition playbook.
And the part that decides the return is not the purchase price, it is what happens after close. Prestige is buying a brand with low integration risk on purpose, which removes most of the danger. But when a buyer acquires something more community-driven or founder-led, the first ninety days after the deal determine whether the equity they paid for survives. Buy a beloved brand and run it through standard corporate process and you can destroy the thing you paid for inside eighteen months. Breathe Right is a reminder that the cleanest returns often come from the least romantic assets.
The biggest consumer check of 2026 went to a nasal strip at a disciplined multiple, financed with debt the brand can pay down itself. Strip away the size and the lesson is small and stubborn: strategics pay for proven, profitable, asset-light demand, and they discount everything else. Build for that buyer, or build knowing you are betting on the exception.
Questions founders and
buyers ask me about
the Breathe Right deal.
Prestige Consumer Healthcare paid $1.045 billion in cash for Breathe Right and certain other over-the-counter brands, acquired from Foundation Consumer Healthcare. Net of an expected $150 million tax benefit, the effective cost is roughly $900 million. The deal was announced on March 20, 2026 and closed on June 15, 2026.
The acquired brands generate about $200 million in revenue and $95 million in EBITDA, so the price works out to roughly 11 times EBITDA and 5.2 times sales. Net of the tax benefit it is closer to 9.5 times EBITDA. That is a disciplined multiple, well below the roughly 22 times EBITDA reportedly paid for Huel, and it reflects a buyer paying for proven, durable cash flow rather than a growth story.
Because a 30-year-old category leader offers exactly what strategics underwrite in this market: demand proven across decades, a roughly 47 percent asset-light EBITDA margin, and distribution that fits the buyer's existing shelf. A DTC brand of similar revenue funded by paid media at a thinner margin gets discounted hard once a corporate finance team models it without the ad spend.
Build for the underwrite. Strategics in 2026 pay large absolute numbers for proven, profitable, asset-light demand and discount growth stories. That means treating margin as a core asset, owning a defensible category position, keeping demand that holds without heavy paid media, and planning around a realistic $300 to $500 million outcome rather than a billion-dollar headline.
Prestige Consumer Healthcare (NYSE: PBH) is a serial owner of durable over-the-counter consumer health brands, including Summer's Eve, Compound W, Clear Eyes and Chloraseptic. Its model is to buy the leader in a small, stable category, fold it onto existing distribution, run it for cash flow, and use that cash to pay down acquisition debt. Breathe Right is now its largest brand.
Building toward an exit, or sizing up a brand to buy?
I have built the kind of brand that ends up on a corporate target list, and closed a several-hundred-million transaction on the buy side. That two-sided view is what shapes every conversation about whether, when, and at what price a deal makes sense.
Start a conversation See the case studies →A note on sources: the $1.045 billion price, the roughly $200 million revenue and $95 million EBITDA on the acquired portfolio, the expected $150 million tax benefit, the Term Loan B financing, and the March 20 announcement and June 15, 2026 close are drawn from Prestige Consumer Healthcare's own press releases and SEC filings. The Huel and Poppi comparison figures are from public reporting on those deals. The read on what the deal means is mine, drawn from building and acquiring consumer brands.